Joint Determinants of Bone Density and CVD Calcification
NCT00037414
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT Number: NCT00005372
To investigate the role of serum and dietary antioxidants, serum pro-oxidants, and smoking on the progression/regression of carotid intima-media thickness (IMT).
Looking for future studies?
Notify MeUp to 100 year
Male
Observational
BACKGROUND:
A finding from the Cholesterol Lowering Atherosclerosis Study (CLAS), a clinical trial, indicated that common carotid intima-media thickness responded more rapidly and more markedly to LDL-C lowering treatment than angiographic coronary stenosis or carotid roughness. New data from a primate model also showed ultrasound detection of intimal thickening in response to a hypercholesterolemic diet within twelve months. These findings suggest that carotid IMT is a reliable and rapidly responding marker of extent of atherosclerosis. However, less than a third of the observed therapeutic benefit on carotid IMT found in CLAS was explained by change in LDL-C and HDL-C, suggesting that related (or other) factors are more directly linked to atherogenic mechanisms. In addition, a Finnish epidemiologic study found that LDL-C was predicative of rate of progression in carotid IMT only in persons with high serum levels of (pro-oxidant) copper. . These and other data support a model of atherosclerosis in which intracellular accumulation of modified LDL is promoted/retarded by serum pro-oxidants/antioxidants.
DESIGN NARRATIVE:
The study tested the specific hypotheses that the positive association between rate of increase in carotid IMT and low density lipoprotein cholesterol (beta deltaIMT/LDL) was greater in persons with [1] higher levels of serum pro-oxidants (relative to persons with lower levels of serum pro-oxidants), [2] lower levels of serum antioxidants, [3] lower levels of dietary antioxidants; and [4] that regression of carotid IMT associated with smoking cessation would be detected in 30 months. Hypothesis were tested with the longitudinal observation of carotid IMT in Hispanic and non-Hispanic white women and men. The inclusion of Hispanics and women was motivated by their prevalence in the study population (18 percent Hispanic, 40 percent women), and by the then recent report that incidence of hospitalization for myocardial infarction was elevated in Hispanics. Seventy three persons from each of four ethnicity-sex groups aged 40-60 years (n-292), and 83 smokers and recent quitters (n-166) were recruited from employees in an ongoing study. Baseline blood, diet and potential confounder variables were related to 18 and 36 month (6, 12, 18, 24 and 30 month in smoker(s) changes in carotid IMT. Levels of antioxidant vitamins, including alpha-tocopherol, ascorbate, and beta carotene, in the plasma were measured at baseline. Plasma levels of negatively charged LDL were measured in a sub-sample of subjects with the most rapidly progressing common carotid intima-media thickness and in an age-sex matched subsample with the least rapidly progressing common carotid intima-media thickness. Finally, an ultrasound measurement of carotid arterial stiffness, another indicator of early atherosclerosis, was developed to address the role of blood pressure.
The Los Angeles Atherosclerosis Study (LAAS) has been renewed through February, 2004 to continue follow-up of the cohort for a total of seven years with two additional measures of arterial dysfunction, including endothelial function of the brachial artery and distensibility or stiffness of the common carotid artery.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
No eligibility criteria
University of Southern California
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00037414
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT00005393
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT00005214
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT00064506
Arterial Occlusive Diseases, Arteriosclerosis
View Trial Details